A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate
A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate
Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.
65-69
Wittman, Brenda
033faa90-58b3-467e-9b9e-e1886e473a71
Horan, John
9b5237a7-ffdb-4b76-9b1c-97951016f5e1
Baxter, Joanna
4d7bbcd3-ca97-4153-82fb-dfb683e49583
Goldberg, John
b540053a-c4be-4575-a164-6f730ea8896b
Felgar, Raymond
3379248f-02b0-4eb2-b562-8c37e927eaae
Baylor, Erin
8bdf967f-3fbe-4026-a887-9cec4fe4011c
Cromwell, Bean
389fbf34-c449-4b83-94ac-e374a4ede3de
Cross, Nicholas
f87650da-b908-4a34-b31b-d62c5f186fe4
Bennett, John M.
3c30c4cb-a0ac-4316-ab2b-27806c8347aa
May 2004
Wittman, Brenda
033faa90-58b3-467e-9b9e-e1886e473a71
Horan, John
9b5237a7-ffdb-4b76-9b1c-97951016f5e1
Baxter, Joanna
4d7bbcd3-ca97-4153-82fb-dfb683e49583
Goldberg, John
b540053a-c4be-4575-a164-6f730ea8896b
Felgar, Raymond
3379248f-02b0-4eb2-b562-8c37e927eaae
Baylor, Erin
8bdf967f-3fbe-4026-a887-9cec4fe4011c
Cromwell, Bean
389fbf34-c449-4b83-94ac-e374a4ede3de
Cross, Nicholas
f87650da-b908-4a34-b31b-d62c5f186fe4
Bennett, John M.
3c30c4cb-a0ac-4316-ab2b-27806c8347aa
Wittman, Brenda, Horan, John, Baxter, Joanna, Goldberg, John, Felgar, Raymond, Baylor, Erin, Cromwell, Bean, Cross, Nicholas and Bennett, John M.
(2004)
A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate.
Leukemia Research, 28 (Supplement 1), .
(doi:10.1016/j.leukres.2003.10.011).
Abstract
Atypical chronic myelogenous leukemia (aCML) is a myelodysplastic/myeloproliferative disorder that usually occurs in older adults. Here we report a pediatric patient with aCML and a t(5;12)(q33;p13) with a corresponding fusion gene ETV6-PDGFRB. Because the PDGFRB tyrosine kinase is one of the known targets of tyrosine kinase inhibitors, this patient achieved cytogenetic and molecular remission with treatment with imatinib mesylate (formerly STI571; now Gleevec in the United States and Glivec in Europe). This case illustrates one of many myelodysplastic/myeloproliferative disorders that can be treated with this particular tyrosine kinase inhibitor.
This record has no associated files available for download.
More information
Published date: May 2004
Identifiers
Local EPrints ID: 60436
URI: http://eprints.soton.ac.uk/id/eprint/60436
ISSN: 0145-2126
PURE UUID: 86dea32f-5610-4671-9c3b-aa8ec69fccd5
Catalogue record
Date deposited: 19 Nov 2008
Last modified: 16 Mar 2024 03:23
Export record
Altmetrics
Contributors
Author:
Brenda Wittman
Author:
John Horan
Author:
Joanna Baxter
Author:
John Goldberg
Author:
Raymond Felgar
Author:
Erin Baylor
Author:
Bean Cromwell
Author:
John M. Bennett
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
